1.

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U.

Science. 2014 Mar 14;343(6176):1221-8. doi: 10.1126/science.1243462. Epub 2014 Feb 20.

PMID: 24557838 Free PMC article.

2.

Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.

Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A, Heikenwalder M.

Cancer Cell. 2014 Oct 13;26(4):549-64. doi: 10.1016/j.ccell.2014.09.003.

PMID: 25314080

3.

New pharmacological strategies to fight enveloped viruses.

Wisskirchen K, Lucifora J, Michler T, Protzer U.

Trends Pharmacol Sci. 2014 Sep;35(9):470-8. doi: 10.1016/j.tips.2014.06.004. Epub 2014 Aug 6.

PMID: 25108320 Free PMC article. Review.

4.

Mouse models for therapeutic vaccination against hepatitis B virus.

Dembek C, Protzer U.

Med Microbiol Immunol. 2015 Feb;204(1):95-102. doi: 10.1007/s00430-014-0378-6. Epub 2014 Dec 19.

PMID: 25523197 Review.

5.

LINE(1)s of evidence in HBV-driven liver cancer.

Heikenwalder M, Protzer U.

Cell Host Microbe. 2014 Mar 12;15(3):249-50. doi: 10.1016/j.chom.2014.02.015.

PMID: 24629329

6.

[Specific degradation of nuclear hepatitis B virus covalently closed circular DNA].

Lucifora J, Xia Y, Reisinger F, Stadler D, Heikenwälder M, Protzer U.

Med Sci (Paris). 2014 Aug-Sep;30(8-9):724-6. doi: 10.1051/medsci/20143008003. Epub 2014 Sep 1.

PMID: 25174742 French. No abstract available.

7.

Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".

Xia Y, Lucifora J, Reisinger F, Heikenwalder M, Protzer U.

Science. 2014 Jun 13;344(6189):1237. doi: 10.1126/science.1254083.

PMID: 24926011

8.

Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.

Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U.

J Hepatol. 2015 Apr;62(4):863-70. doi: 10.1016/j.jhep.2014.11.011. Epub 2014 Nov 22.

PMID: 25463538

9.

Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation.

Protzer U, Böhm F, Longerich T, Seebach J, Heidary Navid M, Friemel J, Marques-Maggio E, Bawohl M, Heikenwalder M, Schirmacher P, Dutkowski P, Clavien PA, Schemmer P, Schnitzler P, Gotthardt D, Müllhaupt B, Weber A.

Mod Pathol. 2015 Apr;28(4):523-32. doi: 10.1038/modpathol.2014.147. Epub 2014 Nov 21.

PMID: 25412844

10.

Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Wuestenberg A, Kah J, Singethan K, Sirma H, Keller AD, Rosal SR, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse AW, Tiegs G, Sass G.

PLoS One. 2014 May 6;9(5):e96533. doi: 10.1371/journal.pone.0096533. eCollection 2014.

PMID: 24801208 Free PMC article.

11.

Monoclonal antibodies to various epitopes of hepatitis B surface antigen inhibit hepatitis B virus infection.

Golsaz Shirazi F, Mohammadi H, Amiri MM, Singethan K, Xia Y, Bayat AA, Bahadori M, Rabbani H, Jeddi-Tehrani M, Protzer U, Shokri F.

J Gastroenterol Hepatol. 2014 May;29(5):1083-91. doi: 10.1111/jgh.12483.

PMID: 24325676

12.

Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo.

Hösel M, Lucifora J, Michler T, Holz G, Gruffaz M, Stahnke S, Zoulim F, Durantel D, Heikenwalder M, Nierhoff D, Millet R, Salvetti A, Protzer U, Büning H.

Hepatology. 2014 Jun;59(6):2110-20. doi: 10.1002/hep.26990. Epub 2014 Apr 30.

PMID: 24425003

13.

HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.

Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C, Ortiz C, Bonaccorsi-Riani E, Brander C, Bauer T, Protzer U, Jaeckel E, Taubert R, Forns X, Navasa M, Berenguer M, Rimola A, Lozano JJ, Sánchez-Fueyo A.

Sci Transl Med. 2014 Jun 25;6(242):242ra81. doi: 10.1126/scitranslmed.3008793.

PMID: 24964989 Clinical Trial.

14.

Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.

Thiele F, Tao S, Zhang Y, Muschaweckh A, Zollmann T, Protzer U, Abele R, Drexler I.

J Virol. 2015 Mar;89(5):2698-709. doi: 10.1128/JVI.03244-14. Epub 2014 Dec 17.

PMID: 25520512 Free PMC article.

15.

Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.

Sprinzl MF, Russo C, Kittner J, Allgayer S, Grambihler A, Bartsch B, Weinmann A, Galle PR, Schuchmann M, Protzer U, Bauer T.

J Viral Hepat. 2014;21(9):633-41. doi: 10.1111/jvh.12189. Epub 2013 Nov 19.

PMID: 24251783